

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Zilucoplan for treating antibody-positive generalised myasthenia gravis [ID4008]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

A patient group commented that it is important to ensure that no patient has to travel excessive distances to receive the treatment given the level of disability that many will face.

The geographical location of treatment centres is not an equalities issue that is within the remit of the committee. However, the committee considered the frequency and method of treatment dosing and the associated impact in its deliberations, particularly when considering the advantages of zilucoplan over intravenous immunoglobulin and plasma exchange.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

The committee considered that myasthenia gravis may have a different burden on women than men. Its considerations of this are detailed in section 3.30 of the draft guidance.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

NA

7. Have the committee's considerations of equality issues been described in the draft guidance, and, if so, where?

Section 3.30 ('Equality')

Approved by Associate Director (name): ...Emily Crowe

Date: 27/06/2024 and 06/11/2024